Wechselwirkungen · Incruse Ellipta (previously Incruse)
Incruse Ellipta 55 micrograms inhalation powder, pre-dispensed · Abschnitt 4.5 · PDF-Seite 5
HOS-220367 · Präparat HOS-216603
Umeclidinium is a substrate of cytochrome P450 2D6 (CYP2D6). The steady-state pharmacokinetics of umeclidinium were assessed in healthy volunteers lacking CYP2D6 (poor metabolisers). No effect on umeclidinium AUC or Cmax was observed at a dose 4-fold higher than the therapeutic dose. An approximately 1.3-fold increase in umeclidinium AUC was observed at an 8-fold higher dose with no effect on umeclidinium Cmax. Based on the magnitude of these changes, no clinically relevant interaction is expected when umeclidinium is co- administered with CYP2D6 inhibitors or when administered to subjects genetically deficient in CYP2D6 activity (poor metabolisers).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-22T12:05:00Z · SHA-256 f26c2fe1443656fc748df1ba079c0d391920fdc3788cc7123b57d1ed9e55e981 · Passage f3c7cef14a3e00a999a5288c3ec05e53a1b32cd960b0f2f4d30b1af89b18ffd9 · Zeichen 596–1296 im Abschnitt